Ligand Pharmaceuticals Incorporated (LGND) — Defensive Interval Ratio
Ligand Pharmaceuticals Incorporated (LGND) has a Defensive Interval Ratio of 3265 days as of June 2026. Defensive assets of $418.07 Million (cash $-, short-term investments $351.06 Million, receivables $67.01 Million) cover 3265 days of daily cash needs of $128.04K/day.
Defensive Interval Ratio
Defensive Assets
Daily Cash Need
Current Liabilities
Ligand Pharmaceuticals Incorporated Defensive Interval Ratio (1994–2025)
This chart shows how Ligand Pharmaceuticals Incorporated's Defensive Interval Ratio has evolved across 30 annual periods from 1994 to 2025. As of June 2026, the ratio stands at 3265 days, meaning defensive assets of $418.07 Million can fund 3265 days of operations without new revenue. For the complete balance sheet picture, see Ligand Pharmaceuticals Incorporated asset portfolio.
Annual Defensive Interval Ratio for Ligand Pharmaceuticals Incorporated (1994–2025)
The table below presents the year-by-year Defensive Interval Ratio for Ligand Pharmaceuticals Incorporated from 1994 to 2025, covering 30 annual filings. Each row shows defensive assets, daily cash need, the DIR in days, and the change in days compared to the prior year. See how liquid is Ligand Pharmaceuticals Incorporated's working capital to evaluate short-term liquidity relative to the company's equity base.
| Year | DIR (days) | Defensive Assets (USD) | Daily Cash Need | Cash | ST Investments | Change (days) |
|---|---|---|---|---|---|---|
| 2025 | 6040 days | $619.64 Million | $102.59K/day | $- | $558.59 Million | ▲ +3814 days |
| 2024 | 2226 days | $226.31 Million | $101.68K/day | $- | $183.86 Million | ▼ -1834 days |
| 2023 | 4060 days | $186.67 Million | $45.98K/day | $- | $147.35 Million | ▲ +3314 days |
| 2022 | 746 days | $201.90 Million | $270.71K/day | $- | $166.86 Million | ▼ -2874 days |
| 2021 | 3620 days | $413.23 Million | $114.15K/day | $- | $321.59 Million | ▲ +2079 days |
| 2020 | 1541 days | $422.63 Million | $274.28K/day | $- | $363.57 Million | ▼ -20787 days |
| 2019 | 22328 days | $1.04 Billion | $46.58K/day | $- | $998.32 Million | ▲ +21875 days |
| 2018 | 453 days | $102.04 Million | $225.34K/day | $- | $46.19 Million | ▲ +131 days |
| 2017 | 322 days | $210.51 Million | $654.43K/day | $- | $181.04 Million | ▲ +96 days |
| 2016 | 225 days | $140.20 Million | $622.27K/day | $- | $122.30 Million | ▼ -1780 days |
| 2015 | 2005 days | $114.47 Million | $57.08K/day | $- | $102.79 Million | ▲ +1672 days |
| 2014 | 333 days | $20.77 Million | $62.41K/day | $- | $7.13 Million | ▲ +196 days |
| 2013 | 137 days | $10.89 Million | $79.28K/day | $- | $4.34 Million | ▲ +17 days |
| 2012 | 120 days | $11.68 Million | $97.09K/day | $- | $2.77 Million | ▼ -67 days |
| 2011 | 188 days | $22.43 Million | $119.57K/day | $- | $10.00 Million | ▼ -151 days |
| 2010 | 339 days | $33.09 Million | $97.62K/day | $- | $19.35 Million | ▲ +6 days |
| 2009 | 333 days | $47.60 Million | $142.94K/day | $- | $37.20 Million | ▲ +2 days |
| 2008 | 331 days | $64.02 Million | $193.46K/day | $- | $51.92 Million | ▲ +102 days |
| 2007 | 228 days | $31.90 Million | $139.64K/day | $- | $17.60 Million | ▲ +166 days |
| 2006 | 62 days | $29.03 Million | $467.97K/day | $- | $13.45 Million | ▼ -2 days |
| 2005 | 64 days | $41.13 Million | $644.41K/day | $- | $20.17 Million | ▼ -22 days |
| 2004 | 86 days | $51.03 Million | $593.73K/day | $- | $20.18 Million | ▼ -313 days |
| 2003 | 399 days | $59.05 Million | $148.08K/day | $- | $40.00 Million | ▲ +50 days |
| 2002 | 349 days | $29.18 Million | $83.66K/day | $- | $21.82 Million | ▲ +41 days |
| 2001 | 308 days | $26.75 Million | $86.92K/day | $- | $16.95 Million | ▼ -43 days |
| 2000 | 350 days | $27.26 Million | $77.85K/day | $- | $14.44 Million | ▲ +15 days |
| 1999 | 335 days | $19.00 Million | $56.71K/day | $- | $17.30 Million | ▲ +253 days |
| 1996 | 82 days | $3.10 Million | $37.81K/day | $- | $- | ▲ +29 days |
| 1995 | 53 days | $2.30 Million | $43.01K/day | $- | $- | ▼ -1 days |
| 1994 | 54 days | $1.20 Million | $22.19K/day | $- | $- | — |